Spring Creek Capital’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Spring Creek Capital’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-140,000	Closed	-$18.4M	–	450
2020 Q4	$18.4M	Buy	+140,000	New	+$12.4M	1.35%	17

Spring Creek Capital's EIDX Position: Q1 2021 in Review

Spring Creek Capital sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 140,000 shares — an estimated $18.4M sold.

Spring Creek Capital first reported a position in EIDX in Q4 2020 and held it in 1 quarter. The position peaked at $18.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Spring Creek Capital reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Spring Creek Capital sold 140,000 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $18.4M.
Spring Creek Capital first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Spring Creek Capital's Eidos Therapeutics, Inc. Common Stock position peaked at $18.4M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Spring Creek Capital's 13F filing for Q1 2021, filed 14 May 2021.